ETO

Summary

Gene Symbol: ETO
Description: RUNX1 translocation partner 1
Alias: AML1-MTG8, AML1T1, CBFA2T1, CDR, ETO, MTG8, ZMYND2, protein CBFA2T1, acute myelogenous leukemia 1 translocation 1, cyclin-D related, core-binding factor, runt domain, alpha subunit 2; translocated to, 1; cyclin D-related, eight twenty one protein, myeloid translocation gene on 8q22, runt related transcription factor 1; translocated to, 1 (cyclin D related), zinc finger MYND domain-containing protein 2
Species: human

Top Publications

  1. ncbi Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells
    Xi Li
    Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine SJTU SM, Shanghai, China
    J Cell Physiol 208:594-601. 2006
  2. doi Sensitivity of acute myeloid leukemia Kasumi-1 cells to binase toxic action depends on the expression of KIT and АML1-ETO oncogenes
    Vladimir A Mitkevich
    Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia
    Cell Cycle 10:4090-7. 2011
  3. ncbi Assembly and function of a TCR alpha enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions
    K Giese
    Howard Hughes Medical Institute, Department of Microbiology, University of California, San Francisco 94143 0414, USA
    Genes Dev 9:995-1008. 1995
  4. ncbi Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt
    P Erickson
    Division of Medical Oncology, University of Colorado Health Sciences and Cancer Center, Denver 80262
    Blood 80:1825-31. 1992
  5. ncbi Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction
    T Kozu
    Department of Immunology and Virology, Saitama Cancer Center Research Institute, Japan
    Blood 82:1270-6. 1993
  6. pmc The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein
    A M Melnick
    Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mol Cell Biol 20:2075-86. 2000
  7. pmc Oligomerization of ETO is obligatory for corepressor interaction
    J Zhang
    Division of Endocrinology, Diabetes, and Metabolism, Departments of Medicine and Genetics, and The Penn Diabetes Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Mol Cell Biol 21:156-63. 2001
  8. ncbi Multiple regions of ETO cooperate in transcriptional repression
    D Hildebrand
    Georg Speyer Haus, Institute for Biomedical Research, Paul Ehrlich Strasse 42 44, 60596 Frankfurt, Germany
    J Biol Chem 276:9889-95. 2001
  9. pmc ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain
    J M Amann
    Department of Biochemistry, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Mol Cell Biol 21:6470-83. 2001
  10. pmc Epigenetic consequences of AML1-ETO action at the human c-FMS locus
    George A Follows
    Molecular Medicine Unit, University of Leeds, St James s University Hospital, Leeds LS9 7TF, UK
    EMBO J 22:2798-809. 2003

Research Grants

  1. Development of a Novel Method for Inhibiting Atherosclerosis in Diabetes
    David R Clemmons; Fiscal Year: 2010
  2. Mucosal Immune Ontogeny and Intestinal Microbiota in Infants
    Edward N Janoff; Fiscal Year: 2010
  3. Role of IG CDR-H3 in Responses to HIV Vaccines
    HARRY WILLIAM SCHROEDER; Fiscal Year: 2013
  4. Mark J Young; Fiscal Year: 2014
  5. Jason T Kimata; Fiscal Year: 2015
  6. Immunoglobulin CDR-H3 and neutralizing antibodies to HIV
    Harry Schroeder; Fiscal Year: 2009
  7. Andrew D Weinberg; Fiscal Year: 2014
  8. A novel pre-defined CDR library for selection of affinity reagents
    Michael P Weiner; Fiscal Year: 2013
  9. PROTEOLYTIC ANTIBODIES FOR TREATMENT OF PSORIASIS
    ROBERT BALINT; Fiscal Year: 2009
  10. ANTIBODY DISPLAY OF PEPTIDE ANTAGONISTS OF IL-1 RECEPTOR
    Jeffry Watkins; Fiscal Year: 1999

Detail Information

Publications244 found, 100 shown here

  1. ncbi Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells
    Xi Li
    Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine SJTU SM, Shanghai, China
    J Cell Physiol 208:594-601. 2006
    AML1-ETO, a fusion protein generated by the chromosomal translocation t(8;21), is frequently associated with acute myeloid leukemia (AML)...
  2. doi Sensitivity of acute myeloid leukemia Kasumi-1 cells to binase toxic action depends on the expression of KIT and АML1-ETO oncogenes
    Vladimir A Mitkevich
    Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia
    Cell Cycle 10:4090-7. 2011
    ..cells FDC-P1; transduced FDC-P1 cells ectopically expressing mutated human KIT N822K oncogene and/or human AML1-ETO oncogene; and human leukemia Kasumi-1 cells expressing both of these oncogenes...
  3. ncbi Assembly and function of a TCR alpha enhancer complex is dependent on LEF-1-induced DNA bending and multiple protein-protein interactions
    K Giese
    Howard Hughes Medical Institute, Department of Microbiology, University of California, San Francisco 94143 0414, USA
    Genes Dev 9:995-1008. 1995
    ....
  4. ncbi Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt
    P Erickson
    Division of Medical Oncology, University of Colorado Health Sciences and Cancer Center, Denver 80262
    Blood 80:1825-31. 1992
    ..The chromosome 8 component, referred to as ETO (for eight twenty-one), is encoded over a large genomic region, as suggested by the analysis of corresponding yeast ..
  5. ncbi Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction
    T Kozu
    Department of Immunology and Virology, Saitama Cancer Center Research Institute, Japan
    Blood 82:1270-6. 1993
    ..The analysis of the cDNAs structure has led to the identification of the fusion of AML1 with a gene named MTG8 on chromosome 8, which seems to be identical to ETO. Northern analysis using MTG8 (ETO) probes detected 7...
  6. pmc The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein
    A M Melnick
    Department of Medicine, Mount Sinai School of Medicine, New York, New York 10029, USA
    Mol Cell Biol 20:2075-86. 2000
    The ETO protein was originally identified by its fusion to the AML-1 transcription factor in translocation (8;21) associated with the M2 form of acute myeloid leukemia (AML)...
  7. pmc Oligomerization of ETO is obligatory for corepressor interaction
    J Zhang
    Division of Endocrinology, Diabetes, and Metabolism, Departments of Medicine and Genetics, and The Penn Diabetes Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Mol Cell Biol 21:156-63. 2001
    ..translocation that combines a sequence-specific DNA binding protein, AML1, with a potent transcriptional repressor, ETO. ETO interacts with nuclear receptor corepressors SMRT and N-CoR, which recruit histone deacetylase to the AML1-ETO ..
  8. ncbi Multiple regions of ETO cooperate in transcriptional repression
    D Hildebrand
    Georg Speyer Haus, Institute for Biomedical Research, Paul Ehrlich Strasse 42 44, 60596 Frankfurt, Germany
    J Biol Chem 276:9889-95. 2001
    ..leukemias (AMLs) with t(8;21), the transcription factor AML1 is juxtaposed to the zinc finger nuclear protein ETO (Eight-Twenty-One), resulting in transcriptional repression of AML1 target genes...
  9. pmc ETO, a target of t(8;21) in acute leukemia, makes distinct contacts with multiple histone deacetylases and binds mSin3A through its oligomerization domain
    J M Amann
    Department of Biochemistry, Vanderbilt Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA
    Mol Cell Biol 21:6470-83. 2001
    t(8;21) and t(16;21) create two fusion proteins, AML-1-ETO and AML-1-MTG16, respectively, which fuse the AML-1 DNA binding domain to putative transcriptional corepressors, ETO and MTG16...
  10. pmc Epigenetic consequences of AML1-ETO action at the human c-FMS locus
    George A Follows
    Molecular Medicine Unit, University of Leeds, St James s University Hospital, Leeds LS9 7TF, UK
    EMBO J 22:2798-809. 2003
    ..In t(8;21) leukaemic cells expressing the aberrant fusion protein AML1-ETO, we demonstrate that this protein is part of a transcription factor complex binding to extended sequences of the c-..
  11. pmc The oncogenic fusion protein RUNX1-CBFA2T1 supports proliferation and inhibits senescence in t(8;21)-positive leukaemic cells
    Natalia Martinez
    Department of Molecular Biology, Institute for Cell Biology, Faculty of Biology, University of Tubingen, Germany
    BMC Cancer 4:44. 2004
    The fusion protein RUNX1-CBFA2T1 associated with t(8;21)-positive acute myeloid leukaemia is a potent inhibitor of haematopoetic differentiation. The role of RUNX1-CBFA2T1 in leukaemic cell proliferation is less clear...
  12. ncbi E protein silencing by the leukemogenic AML1-ETO fusion protein
    Jinsong Zhang
    Laboratory of Biochemistry and Molecular Biology, Rockefeller University, 1230 York Avenue, New York, NY 10021, USA
    Science 305:1286-9. 2004
    The AML1-ETO fusion protein, generated by the t(8;21) chromosomal translocation, is causally involved in nearly 15% of acute myeloid leukemia (AML) cases...
  13. ncbi The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor
    Jill Wildonger
    Center for Neurobiology and Behavior, Columbia University Medical School, New York, NY 10032, USA
    Development 132:2263-72. 2005
    ..Two genes, AML1 and ETO, are fused together at the translocation breakpoint, resulting in the expression of a chimeric protein called AML1-..
  14. pmc Mtgr1 is a transcriptional corepressor that is required for maintenance of the secretory cell lineage in the small intestine
    Joseph M Amann
    Department of Biochemistry, 512 Preston Research Building, Vanderbilt University School of Medicine, 23rd and Pierce Avenue, Nashville, TN 37232, USA
    Mol Cell Biol 25:9576-85. 2005
    Two members of the MTG/ETO family of transcriptional corepressors, MTG8 and MTG16, are disrupted by chromosomal translocations in up to 15% of acute myeloid leukemia cases...
  15. ncbi A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis
    Ming Yan
    Department of Molecular and Experimental Medicine, The Scripps Research Institute, MEM L51, 10550 North Torrey Pines Road, La Jolla, California 92037, USA
    Nat Med 12:945-9. 2006
    ..as AML1, CBFalpha2 or PEBP2alphaB), including its DNA binding domain, and almost the entire RUNX1T1 (also known as MTG8 or ETO) protein...
  16. ncbi Heterochromatic gene repression of the retinoic acid pathway in acute myeloid leukemia
    Francesco Fazi
    San Raffaele Bio medical Park Foundation, Rome, Italy
    Blood 109:4432-40. 2007
    ..Here, we show that AML1/ETO, the most common translocation fusion product in acute myeloid leukemia (AML), counteracts the activity of retinoic ..
  17. ncbi Multi-sites cleavage of leukemogenic AML1-ETO fusion protein by caspase-3 and its contribution to increased apoptotic sensitivity
    Y Lu
    Department of Pathophysiology, Key Laboratory of Cell Differentiation and Apoptosis of Ministry of Education of China, Shanghai Jiao Tong University School of Medicine, Shanghai, China
    Leukemia 22:378-86. 2008
    Leukemia-associated fusion protein AML1-ETO is a product of the chromosome translocation (8;21) frequently occurred in acute myeloid leukemia (AML)...
  18. doi AML1-ETO9a is correlated with C-KIT overexpression/mutations and indicates poor disease outcome in t(8;21) acute myeloid leukemia-M2
    B Jiao
    State Key Laboratory of Medical Genomics, Institute of Health Sciences, Shanghai Institutes for Biological Sciences and Graduate School, Chinese Academy of Sciences and Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
    Leukemia 23:1598-604. 2009
    AML1-ETO fusion gene is generated from chromosomal translocation t(8;21) mainly in acute myeloid leukemia M2 subtype (AML-M2). Its spliced variant transcript, AML1-ETO9a, rapidly induces leukemia in murine model...
  19. doi Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity
    Christian Wichmann
    Institute for Biomedical Research, Georg Speyer Haus, Paul Ehrlich Strasse 42 44, Frankfurt, Germany
    Blood 116:603-13. 2010
    RUNX1/ETO, the fusion protein resulting from the chromosomal translocation t(8;21), is one of the most frequent translocation products in acute myeloid leukemia...
  20. pmc N-Ras(G12D) induces features of stepwise transformation in preleukemic human umbilical cord blood cultures expressing the AML1-ETO fusion gene
    Fu Sheng Chou
    Division of Experimental Hematology and Cancer Biology, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Blood 117:2237-40. 2011
    AML1-ETO (AE) is a fusion product of t(8;21) observed in 40% French-American-British M2 type of acute myeloid leukemia (AML). Clinical data suggest that Ras mutation is a frequent cooperating event in t(8;21) AML...
  21. pmc The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation
    Lan Wang
    Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Science 333:765-9. 2011
    ..We found that AML1-ETO, the fusion protein generated by the t(8;21) translocation, is acetylated by the transcriptional coactivator p300 ..
  22. pmc Depletion of RUNX1/ETO in t(8;21) AML cells leads to genome-wide changes in chromatin structure and transcription factor binding
    A Ptasinska
    Section of Experimental Haematology, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK
    Leukemia 26:1829-41. 2012
    The t(8;21) translocation fuses the DNA-binding domain of the hematopoietic master regulator RUNX1 to the ETO protein...
  23. ncbi Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells
    P E Nisson
    Genome Analysis Laboratory, Life Technologies Inc, Gaithersburg, MD
    Cancer Genet Cytogenet 63:81-8. 1992
    ..of a chromosome 8 gene that contains a region of sequence homology with the cyclin D2 gene, here referred to as the CDR gene (cyclin D-related gene). The chimeric gene is probably responsible for the pathogenesis of the 8;21 AML...
  24. pmc The t(8;21) translocation in acute myeloid leukemia results in production of an AML1-MTG8 fusion transcript
    H Miyoshi
    Department of Immunology and Virology, Saitama Cancer Center Research Institute, Japan
    EMBO J 12:2715-21. 1993
    ..Here we report that this translocation juxtaposes the AML1 gene with a novel gene, named MTG8, on chromosome 8, resulting in the synthesis of an AML1-MTG8 fusion transcript...
  25. ncbi Subcellular localization of the oncoprotein MTG8 (CDR/ETO) in neural cells
    N Sacchi
    Department of Biology and Genetics, School of Medicine, University of Milan, Italy
    Oncogene 16:2609-15. 1998
    ..known as the core binding factor A2 (CBFA2) on chromosome 21, and a gene on chromosome 8, hereafter referred to as MTG8, but also known as CDR and ETO...
  26. ncbi Structure and expression of the human MTG8/ETO gene
    J K Wolford
    Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, AZ 85016, USA
    Gene 212:103-9. 1998
    ..Identical alternatively spliced mRNA variants were found to be produced by the highly conserved homologous gene (Cbfa2t1) in the mouse, suggesting an evolutionary significance.
  27. pmc Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO
    V Gelmetti
    Department of Experimental Oncology, European Institute of Oncology, Milan 20141, Italy
    Mol Cell Biol 18:7185-91. 1998
    ..We report here that ETO (eight-twenty-one or MTG8), which is fused to the acute myelogenous leukemia 1 (AML1) transcription factor in t(8;21) AML, interacts via its ..
  28. ncbi Structure and expression pattern of a human MTG8/ETO family gene, MTGR1
    F Morohoshi
    Radiobiology Division, National Cancer Center Research Institute, Tokyo, Japan
    Gene 241:287-95. 2000
    AML1-MTG8 fusion protein, which is produced from the rearranged gene formed between AML1 and MTG8 in myeloid leukemia with t(8;21) chromosomal translocation, plays an important role in the pathogenesis of leukemia...
  29. pmc AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation
    T Miyamoto
    Departments of Pathology and Developmental Biology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Proc Natl Acad Sci U S A 97:7521-6. 2000
    Leukemia-specific AML1/ETO transcripts are detectable in most patients with t(8;21) acute myelogenous leukemia (AML) in long-term remission...
  30. ncbi Nuclear import and subnuclear localization of the proto-oncoprotein ETO (MTG8)
    Y Odaka
    Department of Biochemistry and Molecular Biology, Louisiana State University Health Science Center School of Medicine, Shreveport 71130, USA
    Oncogene 19:3584-97. 2000
    ETO (MTG8) was first described due to its involvement in the (8;21) translocation frequently observed in acute myeloid leukemias. In the t(8;21) the AML1 gene on chromosome 21 is fused to ETO on chromosome 8...
  31. pmc Atrophin-1, the dentato-rubral and pallido-luysian atrophy gene product, interacts with ETO/MTG8 in the nuclear matrix and represses transcription
    J D Wood
    Division of Neurobiology, Department of Psychiatry, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Cell Biol 150:939-48. 2000
    ..Using the yeast two-hybrid system, we identified ETO/MTG8, a component of nuclear receptor corepressor complexes, as an atrophin-1-interacting protein...
  32. ncbi Analysis of the nuclear distribution of the translocation t(8;21)-derived fusion protein AML1/ETO by confocal laser scanning microscopy
    Stefan Nagel
    Department of Haematology and Oncology, Hannover Medical School, D 30625 Hannover, Germany
    J Hematother Stem Cell Res 11:401-8. 2002
    The AML1/ETO protein derived from the t(8;21) translocation retains the DNA binding domain of AML1, the runt homology domain (RHD), and nearly the complete ETO protein with its four nervy homology regions (NHR1-4)...
  33. ncbi The transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t (16; 21)-positive myeloid malignancies
    Andre T Hoogeveen
    Department of Clinical Genetics, Erasmus University, Rotterdam, The Netherlands
    Oncogene 21:6703-12. 2002
    ..MTG16a, like MTG8, the nuclear corepressor deranged by the t (8; 21), is capable to interact with specific histone deacetylases (..
  34. pmc Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins
    Karina Barseguian
    Department of Cell Biology, University of Massachusetts Medical School, Worcester 01655 0106, USA
    Proc Natl Acad Sci U S A 99:15434-9. 2002
    ..t(8;21) that fuses the N-terminal part of the key hematopoietic regulatory factor AML1 (RUNX1) to the ETO (MTG8) repressor protein...
  35. ncbi AML-associated translocation products block vitamin D(3)-induced differentiation by sequestering the vitamin D(3) receptor
    Elena Puccetti
    Med Klinik III Abtl Hämatologie, Johann Wolfgang Goethe Universitat, 60590 Frankfurt, Germany
    Cancer Res 62:7050-8. 2002
    ..result in formation of chimeric transcription factors, such as PML/RARalpha, PLZF/RARalpha, and AML-1/ETO, of which the components are involved in regulation of transcription by chromatin modeling through histone ..
  36. ncbi ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein
    Nathalie Chevallier
    Department of Medicine, Mount Sinai School of Medicine, One Gustave Levy Pl, New York, NY 10029, USA
    Blood 103:1454-63. 2004
    ..The ETO protein of t(8;21) acute myeloid leukemia (AML) is an excellent candidate as a common factor because it is normally ..
  37. ncbi Interactions between the leukaemia-associated ETO homologues of nuclear repressor proteins
    Sofia Rondin Lindberg
    Department of Hematology, C14, BMC, S 221 84 Lund, Sweden
    Eur J Haematol 71:439-47. 2003
    The eight-twenty-one (ETO) homologues, represented by ETO, myeloid transforming gene-related protein 1 (MTGR1) and myeloid transforming gene chromosome 16 (MTG16), are nuclear repressor proteins...
  38. ncbi The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO
    Jörn Lausen
    Laboratory of Molecular Biophysics, The Rockefeller University, New York, New York 10021, USA
    J Biol Chem 279:49281-8. 2004
    ..The t(8;21) translocation gene product led to the discovery of the Eight Twenty-One (ETO) gene...
  39. ncbi siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts
    J Dunne
    Cancer Research UK Medical Oncology Laboratory, Barts and the London School of Medicine, London, UK
    Oncogene 25:6067-78. 2006
    ..The resultant fusion protein AML1/MTG8 interferes with haematopoietic gene expression and is an important regulator of leukaemogenesis...
  40. pmc The p21Waf1 pathway is involved in blocking leukemogenesis by the t(8;21) fusion protein AML1-ETO
    Luke F Peterson
    Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA 92037, USA
    Blood 109:4392-8. 2007
    ..Multiple mouse models using this fusion protein demonstrate that AML1-ETO requires secondary mutagenic events to promote leukemogenesis...
  41. pmc Myeloid translocation gene family members associate with T-cell factors (TCFs) and influence TCF-dependent transcription
    Amy C Moore
    Department of Biochemistry, 512 Preston Research Building, Vanderbilt University School of Medicine, 2220 Pierce Ave, Nashville, TN 37232, USA
    Mol Cell Biol 28:977-87. 2008
    ..translocations in acute myeloid leukemia, whereas MTG16 may be inactivated in up to 40% of breast cancer and MTG8 is a candidate cancer gene in colorectal carcinoma...
  42. pmc The leukemia associated ETO nuclear repressor gene is regulated by the GATA-1 transcription factor in erythroid/megakaryocytic cells
    Ram Ajore
    1Department of Hematology, C14, BMC, S 221 84 Lund, Sweden
    BMC Mol Biol 11:38. 2010
    The Eight-Twenty-One (ETO) nuclear co-repressor gene belongs to the ETO homologue family also containing Myeloid Translocation Gene on chromosome 16 (MTG16) and myeloid translocation Gene-Related protein 1 (MTGR1)...
  43. ncbi AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein
    A Melnick
    Department of Medicine, The Derald H Ruttenberg Cancer Center, Mount Sinai School of Medicine, New York, NY 10029, USA
    Blood 96:3939-47. 2000
    The AML-1/ETO fusion protein, created by the (8;21) translocation in M2-type acute myelogenous leukemia (AML), is a dominant repressive form of AML-1...
  44. ncbi The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells
    Alex Tonks
    Department of Haematology, University of Wales College of Medicine, Cardiff, United Kingdom
    Blood 101:624-32. 2003
    The t(8;21) translocation, which encodes the AML1-ETO fusion protein (now known as RUNX1-CBF2T1), is one of the most frequent translocations in acute myeloid leukemia, although its role in leukemogenesis is unclear...
  45. pmc The human SIN3B corepressor forms a nucleolar complex with leukemia-associated ETO homologues
    Rakesh Singh Dhanda
    Department of Hematology, C14, BMC, SE 221 84 Lund, Sweden
    BMC Mol Biol 9:8. 2008
    ..The purpose of this work was to study possible interactions between corepressors human SIN3B (hSIN3B) and the ETO homologues - ETO (eight twenty-one), MTG16 (myeloid-transforming gene 16) and MTGR1 (MTG-related protein 1)...
  46. pmc AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets
    Alessandro Gardini
    Department of Experimental Oncology, IEO European Institute of Oncology, Milan, Italy
    PLoS Genet 4:e1000275. 2008
    A reciprocal translocation involving chromosomes 8 and 21 generates the AML1/ETO oncogenic transcription factor that initiates acute myeloid leukemia by recruiting co-repressor complexes to DNA...
  47. ncbi Gfi-1 attaches to the nuclear matrix, associates with ETO (MTG8) and histone deacetylase proteins, and represses transcription using a TSA-sensitive mechanism
    Laura McGhee
    The Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center Shreveport, 1501 Kings Highway, Shreveport, LA 71130, USA
    J Cell Biochem 89:1005-18. 2003
    ..ETO (also termed MTG8), was first identified through its involvement in the (8;21) translocation associated with acute myelogenous ..
  48. ncbi The Leukemia-associated ETO homologues are differently expressed during hematopoietic differentiation
    Sofia Rondin Lindberg
    Department of Hematology, University of Lund, Lund, Sweden
    Exp Hematol 33:189-98. 2005
    The Eight twenty-one (ETO) homologues are nuclear repressor proteins including ETO, myeloid-transforming gene-related protein 1 (MTGR1), and myeloid-transforming gene chromosome 16 (MTG16)...
  49. ncbi Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia
    Shujun Liu
    Divisions of Hematology Oncology, Department of Internal Medicine and the Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA
    Cancer Res 65:1277-84. 2005
    ..t(8;21)(q22;q22) in acute myeloid leukemia (AML) results in the expression of the fusion protein RUNX1/MTG8, which in turn recruits histone deacetylases (HDAC) to silence RUNX1 target genes [e.g., interleukin-3 (IL-3)]...
  50. ncbi [Immunophenotypic features of acute myeloid leukemia with AML-1/ETO fusion gene]
    Jian Jun Zhang
    Flow Cytomertry Laboratory, Department of Laboratory Medical Examination, Guangdong Provincial People s Hospital, Guangzhou 510080, China
    Zhongguo Shi Yan Xue Ye Xue Za Zhi 15:378-81. 2007
    AML-1/ETO fusion gene is the frequent genetic lesion described in FBA M(2) type acute myeloid leukemia (AML-M(2)) and is associated with a favourable prognosis...
  51. ncbi The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia
    Lidia Larizza
    Department of Biology and Genetics for Medical Sciences, Medical Faculty, University of Milan, Italy
    Leuk Lymphoma 46:247-55. 2005
    ..molecular, morphologic, immunophenotypic findings of AML with t(8;21) and the functional consequences of the AML1-ETO fusion oncogene on myeloid differentiation...
  52. ncbi An investigation into the acute nootropic effects of Hypericum perforatum L. (St. John's Wort) in healthy human volunteers
    K A Ellis
    Neuropharmacology Laboratory, Brain Sciences Institute, Swinburne University of Technology, Hawthorn, Victoria, Australia
    Behav Pharmacol 12:173-82. 2001
    ..Twelve healthy young subjects completed the Cognitive Drug Research (CDR) memory battery, following administration of placebo, 900 mg and 1800 mg hypericum (Blackmore's Hyperiforte)...
  53. ncbi AML1/ETO Fusion Gene in de novo Pediatric Acute Myeloid Leukemia: Clinical Significance and Prognostic Implications
    Hany Abdel Rahman
    The Departments of Pediatric Oncology, National Cancer Institute, Cairo University, Cairo, Egypt
    J Egypt Natl Canc Inst 19:39-47. 2007
    ..The aim of this work is to study the frequency of AML1/ETO fusion gene in a series of Egyptian childhood AML cases...
  54. ncbi Dementia and work load evaluation of the elderly
    H A Nygaard
    Fyllingsdalen Sykehjem, Bergen, Norway
    Compr Gerontol A 1:65-8. 1987
    ..Mental status was estimated by means of the Clinical Dementia Rating scale (CDR), and work load by means of a traditional work load scale...
  55. ncbi [Occupational medicine studies of 7 ethylene oxide-exposed endoscopy nursing professionals]
    M Wagner

    Zentralbl Bakteriol Mikrobiol Hyg B 185:154-63. 1987
    For 7 working days running the ethyleneoxide (EtO) concentration has been determined in a medium sized sterilization plant of a medical endoscopy department. Sampling was taken from passive collectors of 3 M...
  56. ncbi Testicular damage caused by inhalation of ethylene oxide in rats: light and electron microscopic studies
    M Kaido
    Department of Pathology and Toxicologic Pathology, School of Medicine, University of Occupational and Environmental Health, Japan
    Toxicol Pathol 20:32-43. 1992
    Although testicular damage caused by ethylene oxide vapor (EtO) has been previously reported, the morphological changes occurring in seminiferous tubules remain unclear...
  57. ncbi Acquired cadmium resistance in metallothionein-I/II(-/-) knockout cells: role of the T-type calcium channel Cacnalpha1G in cadmium uptake
    Elaine M Leslie
    Inorganic Carcinogenesis Section, Laboratory of Comparative Carcinogenesis, National Cancer Institute and National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA
    Mol Pharmacol 69:629-39. 2006
    ..In the current study, Cd(2+)-resistant MT(-/-) (CdR) and CdR revertant (CdR-rev) cell lines were developed and characterized to investigate non-MT-mediated cellular ..
  58. ncbi [Detection of common fusion transcript levels in untreated leukemia patients by real-time quantitative RT-PCR technique]
    Ya Zhen Qin
    Institute of Hematology, People s Hospital of Peking University, Beijing 10004, China
    Zhonghua Xue Ye Xue Za Zhi 28:433-7. 2007
    To evaluate levels of common specific fusion transcripts M-bcr-abl, m-bcr-abl, TEL-AML1, AML1-ETO, PML-RAR alpha, CBF beta-MYH11 in untreated leukemia patients.
  59. ncbi The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias
    F Lo Coco
    Department of Human Biopathology, University La Sapienza of Rome, Italy
    Haematologica 82:364-70. 1997
    ..In the t(8;21), AML1 is fused to the ETO (MTG8) gene, resulting in a hybrid AML1/ETO mRNA, which in turn is translated into a chimeric protein...
  60. ncbi The Cohen diabetic (non-insulin-dependent) hypertensive rat model. Description of the model and pathologic findings
    A M Cohen
    Department of Medicine, Hebrew University, Hadassah Medical School, Jerusalem, Israel
    Am J Hypertens 6:989-95. 1993
    ..here a genetic type II diabetic hypertensive model (CDHM) developed by cross breeding the Cohen diabetic rat (CDR) and the SHR...
  61. ncbi Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study
    K Mrozek
    Division of Hematology and Oncology, Comprehensive Cancer Center, Ohio State University, Columbus, OH 43210 1228, USA
    J Clin Oncol 19:2482-92. 2001
    ....
  62. ncbi Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR)
    O Hanon
    Department of Geriatrics, Hopital Broca, 75013 Paris, France
    J Nutr Health Aging 9:106-11. 2005
    ..To determine the evolution of blood pressure in patients with moderate Alzheimer's disease among a one year longitudinal survey and to evaluate the relationship between blood pressure and cognitive functions...
  63. ncbi Diagnostic strategy using a modified clinical decision rule and D-dimer test to rule out pulmonary embolism in elderly in- and outpatients
    Maaike Sohne
    Academic Medical Center, Department of Vascular Medicine, Room F4 136, Meibergdreef 9, 1105 AZ Amsterdam
    Thromb Haemost 94:206-10. 2005
    ..The safety and efficacy of the combination of a clinical probability (CDR) and d-dimer test in excluding pulmonary embolism in this group is unclear...
  64. ncbi [5-aza-2'-deoxycytidine induces changes of histone H3-lysine 9 methylation in bladder tumor cells]
    Na Yang
    Department of Clinical Laboratory Medicine, Shanghai Tenth People s Hospital, Tongji University, Shanghai 200072, China
    Zhonghua Yi Xue Za Zhi 88:2295-8. 2008
    To investigate the effect of DNA methyltransferases inhibitor 5-aza-2'-deoxycytidine (5-Aza-CdR) on the histone H3-lysine 9 methylation status and gene expression of RUNX3 in human bladder tumor cells.
  65. ncbi Fluid absorption study in ultra-high molecular weight polyethylene (UHMWPE) sterilized and unsterilized acetabular cups
    S Affatato
    Laboratorio di Tecnologia Medica, Istituti Ortopedici Rizzoli, Bologna, Italy
    Proc Inst Mech Eng H 215:107-11. 2001
    The weight gain due to fluid absorption was measured in gamma-sterilized, ethylene oxide (ETO) gas-sterilized, and unsterilized ultra-high molecular weight (UHMW) polyethylene acetabular cups...
  66. doi Inhibition of cytidine deaminase by zebularine enhances the antineoplastic action of 5-aza-2'-deoxycytidine
    Maryse Lemaire
    Departement de Pharmacologie, Universite de Montreal, QC, Canada
    Cancer Chemother Pharmacol 63:411-6. 2009
    ..deaminase with respect to the antineoplastic action of inhibitors of DNA methylation, 5-aza-2'-deoxycytidine (5-AZA-CdR) and zebularine. Zebularine has a dual mechanism of action, since it can also inhibit CR deaminase...
  67. ncbi Combination of a thiazide, a vasodilator and reserpine compared with methyldopa plus hydrochlorothiazide in the treatment of hypertension in Zimbabwe
    C M Stein
    Department of Clinical Pharmacology, University of Zimbabwe, Harare
    S Afr Med J 77:243-5. 1990
    ..5 mg) and reserpine (0.1 mg) (CDR) was compared with methyldopa (MD) plus hydrochlorothiazide (HCT) for antihypertensive effect, adverse reactions, ..
  68. ncbi Non-neurological factors are implicated in impairments in gait and mobility among patients in a clinical dementia referral population
    Vince Salazar Thomas
    Division of Geriatric Epidemiology, Neurotec, Karolinska Institutet and Stockholm Gerontology Research Center, Stockholm, Sweden
    Int J Geriatr Psychiatry 17:128-33. 2002
    ..Gait disorders were very prevalent at each level of cognitive function [58.7% for CDR=0, 68.0% for CDR=0.5, 57.9% for CDR=1, 68.1% for CDR=2 and 76.9% for CDR=3, p=0...
  69. ncbi Interaction of lysozyme with synthetic anti-lysozyme D1.3 antibody fragments studied by affinity chromatography and surface plasmon resonance
    E Lasonder
    Laboratory of Medical Microbiology, University of Groningen, Netherlands
    J Chromatogr A 676:91-8. 1994
    ..3 show interaction with lysozyme. Surface plasmon resonance with immobilized CDR peptides showed that this interaction is not based on the antigen-antibody interaction...
  70. ncbi Isolation and characterization of cloned cDNAs encoding human liver chlordecone reductase
    C J Winters
    Department of Medicine, Medical College of Virginia, Richmond 23298
    Biochemistry 29:1080-7. 1990
    ..This reaction is controlled by a cytosolic enzyme, chlordecone reductase (CDR), which may be of the aldo-keto reductase family of xenobiotic metabolizing enzymes [Molowa et al. (1986) J. Biol...
  71. ncbi Reactions of actinide ions with ethylene oxide
    J K Gibson
    Chemical and Analytical Sciences Division, Oak Ridge National Laboratory, P O Box 2008, Building 5505, MS 6375, Oak Ridge, Tennessee 37831 6375, USA
    J Mass Spectrom 36:284-93. 2001
    Naked and oxo-ligated actinide (An) monopositive ions were reacted with ethylene oxide, cyclo-C(2)H(4)O (EtO). Along with An = U, Np, Pu and Am, ions of two lanthanide (Ln) elements, Ln = Tb and Tm, were studied for comparison...
  72. ncbi 5-Aza-2'-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia
    Karin Schmelz
    Department of Hematology and Oncology, Universitatsmedizin Berlin, Charite, Campus Virchow, Berlin, Germany
    Int J Cancer 114:683-95. 2005
    The DNA methylation inhibitor 5-Aza-2'-deoxycytidine (5-Aza-CdR) has significant therapeutic value for the treatment of patients with myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and chronic myeloid leukemia (CML)...
  73. ncbi [A longitudinal study of the course of Alzheimer type dementia]
    J A Tellería-Díaz
    Hospital Clinico Quirurgico Hermanos Ameijeiras, La Habana, Cuba
    Rev Neurol 25:1551-6. 1997
    ..We carried out a prospective longitudinal study of 41 patients diagnosed as probably having a mild form of Alzheimer's disease according to the data of an investigation of prevalence done in 1991 in the municipality of Habana Vieja...
  74. ncbi [PRAME mRNA expression in newly diagnosed acute myeloid leukemia patients and its application to monitoring minimal residual disease]
    Ya Zhen Qin
    Institute of Hematology, People s Hospital of Peking University, Beijing 100044, China
    Zhonghua Xue Ye Xue Za Zhi 29:441-5. 2008
    ..To investigate the expression level of preferentially expressed antigen of melanoma (PRAME) mRNA in newly diagnosed acute myeloid leukemia (AML) patients and evaluate its usefulness for detecting minimal residual disease (MRD)...
  75. doi Analysis of paediatric drowning deaths in Washington State using the child death review (CDR) for surveillance: what CDR does and does not tell us about lethal drowning injury
    Linda Quan
    University of Washington School of Medicine, Seattle, USA
    Inj Prev 17:i28-33. 2011
    Drowning is second cause of paediatric injury death in Washington State. Child death review (CDR) data provide the unique opportunity to identify regional risk factors and opportunities for drowning prevention.
  76. ncbi Effect of Size on the Biodistribution and Blood Clearance of Etoposide-Loaded PLGA Nanoparticles
    Khushwant S Yadav
    TIFAC Centre of Relevance and Excellence in NDDS, Pharmacy Department, The M S University of Baroda, Fatehgunj, Vadodara, Gujarat, India
    PDA J Pharm Sci Technol 65:131-9. 2011
    ..particle size of etoposide-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) of sizes 105 nm ((99m)Tc-Eto-PLGA NP(105)) and 160 nm ((99m)Tc-Eto-PLGA NP(160)) on biodistribution and blood clearance were studied after ..
  77. ncbi Comparison of liquid chemical sterilization with peracetic acid and ethylene oxide sterilization for long narrow lumens
    M J Alfa
    St Boniface Research Centre, Winnipeg, MB, Canada
    Am J Infect Control 26:469-77. 1998
    ..65% salt challenge (RPMI-S) compared with a 100% ethylene oxide (ETO) sterilizer and an ETO hydrochlorofluorocarbon (ETO-HCFC) sterilization method with long (125 cm), narrow (3-mm ..
  78. doi Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada
    Fiona M Clement
    Department of Medicine, University of Calgary, Calgary, Alberta, Canada
    JAMA 302:1437-43. 2009
    ..This study describes how that evidence has been used across 3 jurisdictions (Australia, Canada, and Britain) that have been at the forefront of evidence-based coverage internationally...
  79. ncbi [Effects and mechanisms of 5-aza-2'-deoxycytidine on endometrial cancer cell.]
    Yu Quan Zhang
    Department of Obstetrics and Gynecology, Affiliated Hospital of Nantong University, Nantong 226000, China Email
    Zhonghua Fu Chan Ke Za Zhi 44:861-4. 2009
    To investigate the effects and mechanisms of 5-aza-2'-deoxycytidine (5-Aza-CdR) on endometrial cancer cell.
  80. ncbi Using the cost distribution report in estimating private sector payments: what adjustments should researchers make?
    Gary Nugent
    Nebraska Western Iowa Health Care System, Omaha, NE, USA
    Med Care 41:II80-90. 2003
    ..To reapportion Veterans Health Administration (VA) annual expenditures into benefit categories for comparison with estimated payments by private sector providers...
  81. ncbi Corpus callosum atrophy, white matter lesions, and frontal executive dysfunction in normal aging and Alzheimer's disease. A community-based study: the Tajiri Project
    Kenichi Meguro
    Division of Neuropsychology, Department of Disability Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
    Int Psychogeriatr 15:9-25. 2003
    ..We investigated the relationship between CC atrophy, WMH, and hippocampal atrophy, together with frontal executive dysfunction in both normal aging and AD...
  82. ncbi 5-HT2A/2C receptor and 5-HT transporter densities in mice prone or resistant to chronic high-fat diet-induced obesity: a quantitative autoradiography study
    Xu Feng Huang
    Molecular Neurobiology Laboratory, Smart Food Center, Department of Biomedical Science, University of Wollongong, Northfield Avenue, Wollongong, NSW 2522, Australia
    Brain Res 1018:227-35. 2004
    ..receptors and 5-HT transporters in the brains of chronic high-fat diet-induced obese (cDIO) and obese-resistant (cDR) mice. Thirty-five male mice were used in this study...
  83. ncbi Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications
    Ester Fonsatti
    Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy
    Clin Cancer Res 13:3333-8. 2007
    To investigate the potential of the DNA hypomethylating agent 5-aza-2'-deoxycytidine (5-aza-CdR) to improve the effectiveness of immunotherapeutic approaches against melanocyte differentiation antigens.
  84. pmc New methods for estimating the tuberculosis case detection rate in high-HIV prevalence countries: the example of Kenya
    John Mansoer
    US Department of Health and Human Services, Centers for Disease Control and Prevention, Nairobi, Kenya
    Bull World Health Organ 87:186-92, 192A-192B. 2009
    To develop new methods for estimating the sputum smear-positive tuberculosis case detection rate (CDR) in a country where infection with HIV is prevalent.
  85. doi 3-Deazauridine enhances the antileukemic action of 5-aza-2'-deoxycytidine and targets drug-resistance due to deficiency in deoxycytidine kinase
    Noel J M Raynal
    Service of Hematology and Oncology, Université de Montréal and Centre de Recherche, CHU Saint Justine, 3175 Ste Catherine Road, Montreal, Quebec, H3T 1C5 Canada
    Leuk Res 35:110-8. 2011
    ..methylation plays an important role in leukemogenesis of ALL, it can be targeted by 5-aza-2'-deoxycytidine (5-AZA-CdR), a potent inhibitor of DNA methylation. 5-AZA-CdR is a prodrug that is activated by deoxycytidine kinase (DCK)...
  86. ncbi Effects of three epoxides--ethylene oxide, propylene oxide and epichlorohydrin--on cell cycle progression and cell death in human diploid fibroblasts
    P Mlejnek
    Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno
    Chem Biol Interact 117:219-39. 1999
    Ethylene oxide (EtO), propylene oxide (PO), and epichlorohydrin (ECH) strongly influenced the G1/S progression in human diploid fibroblasts, VH-10. However, these epoxides did not affect substantially the G2/M progression...
  87. ncbi Assessment of cancer risk from ethylene oxide residues in spices imported into New Zealand
    J Fowles
    Institute of Environmental Science and Research, PO Box 50 348, Porirua, New Zealand
    Food Chem Toxicol 39:1055-62. 2001
    Quantitative estimates of cancer risks from ethylene oxide (ETO) residues were constructed based on 200 retail samples of various spices in New Zealand. Two samples of cinnamon contained detectable ETO...
  88. ncbi A novel monoclonal antibody design for radioimmunotherapy
    Andres Forero
    Department of Medicine, Division of Hematology Oncology, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA
    Cancer Biother Radiopharm 18:751-9. 2003
    The generation of chimeric and complementary-determining region (CDR) grafted monoclonal antibodies (MAb) have reduced the immunogenicity problem in the clinical application of radioimmunotherapy with monoclonal antibodies...
  89. pmc Utility of the clinical dementia rating in Asian populations
    Wee Shiong Lim
    Department of Geriatric Medicine, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433
    Clin Med Res 5:61-70. 2007
    ..The Clinical Dementia Rating (CDR) is an informant-based global assessment scale with established reliability and validity that has been widely ..
  90. pmc The "portable" CDR: translating the clinical dementia rating interview into a PDA format
    James E Galvin
    Alzheimer Disease Research Center, Washington University School of Medicine, 4488 ForestPark, Suite 130, St Louis, MO 63108, USA
    Alzheimer Dis Assoc Disord 23:44-9. 2009
    The Clinical Dementia Rating (CDR) is a common rating system used in clinical trials and longitudinal research projects to rate the presence and severity of cognitive problems in Alzheimer disease and related disorders...
  91. ncbi Medicine reimbursement recommendations in Canada, Australia, and Scotland
    Joel Lexchin
    School of Health Policy and Management, York University, 4700 Keele St, Toronto, Ontario, Canada M3J 1P3
    Am J Manag Care 14:581-8. 2008
    This study was undertaken to compare the recommendations made by the Canadian Common Drug Review (CDR) regarding whether drugs should be listed on provincial and federal formularies with recommendations made by similar bodies in other ..
  92. doi Biochemical markers in persons with preclinical familial Alzheimer disease
    J M Ringman
    UCLA Department of Neurology, Alzheimer Disease Research Center, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
    Neurology 71:85-92. 2008
    ..Persons at risk for familial Alzheimer disease (FAD) provide a model in which biomarkers can be studied in presymptomatic disease...
  93. doi Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve
    Anthony F Fotenos
    Division of Biology and Biomedical Sciences, Washington University Medical School, St Louis, Missouri, USA
    Arch Neurol 65:113-20. 2008
    ..To assess the relation between socioeconomic status (SES) and structural brain change in nondemented older adults and to ascertain the potential role of preclinical Alzheimer disease (AD)...
  94. ncbi Differential expression of dopamine D2 and D4 receptor and tyrosine hydroxylase mRNA in mice prone, or resistant, to chronic high-fat diet-induced obesity
    Xu Feng Huang
    Department of Biomedical Science, Molecular Neurobiology Laboratory, University of Wollongong, NSW2522, Australia
    Brain Res Mol Brain Res 135:150-61. 2005
    ..and tyrosine hydroxylase (TH) mRNA expression in chronic high-fat diet-induced obese (cDIO) and obese-resistant (cDR) mice...
  95. ncbi Behavioral and psychological symptoms of dementia characteristic of mild Alzheimer patients
    Jin Shimabukuro
    Department of Psychiatry, Tohoku University Hospital, Sendai, Japan
    Psychiatry Clin Neurosci 59:274-9. 2005
    ..BPSD) in patients with mild Alzheimer's disease (AD), BPSD among the severities of Clinical Dementia Rating (CDR) in 74 patients with AD were compared using the Neuropsychiatric inventory (NPI)...
  96. ncbi An audit of intra-oral digital radiographs for endodontics
    R Austin
    Department of Primary Dental Care, King s College London Dental Institute, London, UK
    Int Endod J 43:351. 2010
    ..There were three phases. The first phase compared the Schick CDR system with Digora Optime...
  97. pmc Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo
    Bushra Ateeq
    Department of Medicine, McGill University, Montreal, Quebec, Canada
    Neoplasia 10:266-78. 2008
    The mechanism of action of DNA methylation inhibitor 5-aza-2'-deoxycytidine (5-aza-CdR), a potential anticancer agent is believed to be activated by the demethylation of tumor suppressor genes...
  98. ncbi Evaluation of a data warehouse in an academic health sciences center
    J R Schubart
    Department of Health Evaluation Sciences, University of Virginia School of Medicine, P O Box 800717, Charlottesville, VA 22908 0717, USA
    Int J Med Inform 60:319-33. 2000
    The Clinical data repository (CDR) at the University of Virginia Health System is a data warehouse that provides direct access to data for clinical research and effective decision making...
  99. ncbi Pharmacokinetics of intravenous etoposide in patients with breast cancer: influence of dose escalation and cyclophosphamide and doxorubicin coadministration
    Dagmar Busse
    Dr Margarete Fischer Bosch Institute of Clinical Pharmacology, Auerbachstrasse 112, 70376 Stuttgart, Germany
    Naunyn Schmiedebergs Arch Pharmacol 366:218-25. 2002
    ..of dose escalation and of doxorubicin and cyclophosphamide coadministration on the pharmacokinetics of etoposide (ETO)...
  100. ncbi The clinical dementia rating sum of box score in mild dementia
    C A Lynch
    Mercer s Institute for Research on Ageing, St James s Hospital, Dublin, Ireland
    Dement Geriatr Cogn Disord 21:40-3. 2006
    ..The Clinical Dementia Rating (CDR) scale is a widely used dementia staging instrument, yielding a global score and a summated score (sum of box score)..
  101. ncbi Decreased response of osteoblasts obtained from aged Cohen diabetic sensitive rats to sex steroid hormones and 1,25OH2D3 in culture
    Asher Ornoy
    Laboratory of Teratology, Department of Anatomy and Cell Biology, Hebrew University Hadassah Medical School, P O B 12272, 91120 Jerusalem, Israel
    Odontology 94:38-43. 2006
    ..The Cohen diabetic model consists of a diabetic-sensitive strain [CDs; diabetic] and a diabetic-resistant strain [CDr; normal])...

Research Grants73

  1. Development of a Novel Method for Inhibiting Atherosclerosis in Diabetes
    David R Clemmons; Fiscal Year: 2010
    ..structure of the antibody will be undertaken to determine those residues that are within 10 angstroms of the CDR antigen binding site. These residues will also be modified to reduce their interaction with the binding domain...
  2. Mucosal Immune Ontogeny and Intestinal Microbiota in Infants
    Edward N Janoff; Fiscal Year: 2010
    ..In B cells, immunoglobulin genes, particularly the 3 hypervariable complementarity determining regions (CDR) of heavy chains (VH), show the greatest diversity and contribute most to antigen binding5...
  3. Role of IG CDR-H3 in Responses to HIV Vaccines
    HARRY WILLIAM SCHROEDER; Fiscal Year: 2013
    ..the norm in that each of their antigen binding sites contain a long, H chain complementarity determining region 3 (CDR-H3) that lacks tyrosine and includes patches of hydrophobic and charged amino acids...
  4. Mark J Young; Fiscal Year: 2014
    ..2) Antibody CDR dimers (Specific aim 2)...
  5. Jason T Kimata; Fiscal Year: 2015
    ..data indicate that targeting single-chain Fv (scFv) or the heavy chain third complementarity-determining region (CDR H3) of some anti-HIV-1 Env MAbs to lipid rafts with a glycosyl-phosphatidyl-inositol (GPI)-anchor enhances their ..
  6. Immunoglobulin CDR-H3 and neutralizing antibodies to HIV
    Harry Schroeder; Fiscal Year: 2009
    ..that each of their antigen binding sites contain a long, hydrophobic H chain complementarity determining region 3 (CDR-H3)...
  7. Andrew D Weinberg; Fiscal Year: 2014
    ..humanization of the anti-OX40 antibody after insertion of the identical murine antibody's variable region CDR sequences into human IgG frameworks, assessment of OX40 binding and bioactivity in vitro, and development of a ..
  8. A novel pre-defined CDR library for selection of affinity reagents
    Michael P Weiner; Fiscal Year: 2013
    ..We have termed this new library-type as a 'pre-defined CDR'(PDC) library...
  9. PROTEOLYTIC ANTIBODIES FOR TREATMENT OF PSORIASIS
    ROBERT BALINT; Fiscal Year: 2009
    ..repertoire contain canonical serine protease-like catalytic triads in their complementarity-determining regions (CDR), and some have detectable peptidolytic activity...
  10. ANTIBODY DISPLAY OF PEPTIDE ANTAGONISTS OF IL-1 RECEPTOR
    Jeffry Watkins; Fiscal Year: 1999
    ..Display of the peptides within the third complementarity-determining region (CDR) of the heavy chain will be optimized by synthesis of expression libraries in which the CDR positions of the ..
  11. Longitudinal study of membrane lipids: pre-clinical Alzheimer's biomarkers
    Michelle M Mielke; Fiscal Year: 2010
    ..and our preliminary data, suggest these lipids are altered in blood, CSF and brain in the earliest stages of AD (CDR 0.5), and vary by AD severity...
  12. Suzanne Craft; Fiscal Year: 2016
    ..Two-hundred and forty participants with aMCI (Petersen criteria, Clinical Dementia Rating/CDR 0.5) or mild AD (NINDS-ADRDA criteria, CDR 0.5-1.0, Mini-mental State Exam20) will be enrolled...
  13. GROVER CLEVELAND GILMORE; Fiscal Year: 2015
    ..Patients will be stratified by AD severity (CDR mild or moderate) and cataract severity (LOCS 1-2 or 3-4) prior to being randomized...
  14. Mark I Greene; Fiscal Year: 2015
    ..We will use a fragment of human HER2 that is structurally like a CDR and link it to human Fc fragments...
  15. Yvette I Sheline; Fiscal Year: 2015
    ..placebo controlled trial of 54 cognitively normal participants, age 65- 80, (Clinical Dementia Rating scale, [CDR] = 0) recruited from the Washington University ADRC...
  16. Conversational Engagement as a Means to Delay Alzheimer's Disease Onset
    HIROKO HAYAMA DODGE; Fiscal Year: 2012
    ..Aim 2. Among those interviewed in Aim 1, we will recruit 80 subjects with Clinical Dementia Rating Scale (CDR) = 0 and 80 subjects with CDR = 0.5 from the lower end of the social engagement frequencies...
  17. Aberrant hematopoiesis: E proteins and AML1-ETO in leukemogenesis
    Jinsong Zhang; Fiscal Year: 2013
    ..This translocation generates an AML1-ETO fusion protein by joining part of the AML1/RUNX1 transcription factor to a nearly complete ETO protein, the ..
  18. Functional Decline in Three Dementia Types
    WALTER ANTHONY KUKULL; Fiscal Year: 2012
    ..of probable AD, probable VaD, or DLB);2) age 60+ years (visit 1);3) Clinical Dementia Rating-Sum of Boxes (CDR-SOB) score <16 (visit 1);and 4) time between successive visits restricted to 0.5-1.5 years...
  19. Age related Cognitive Loss in Mumbai, India
    Dushyant P Purohit; Fiscal Year: 2010
    ..who come to autopsy and are free of cognitive impairment (based on a postmortem Clinical Dementia Rating Score or CDR of 0)...
  20. JAMES DOUGLAS GRIFFIN; Fiscal Year: 2016
    ..cooperation of these alleles with other leukemia associated alleles, such as PML-RARa, C/EBPa, MLL and AML1-ETO, and in developing accurate murine models of JAK2V617F MPD for testing inhibitors developed in Project 1...
  21. Stephen D Nimer; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): PI: Stephen D. Nimer, MD ABSTRACT The leukemogenic AML1-ETO fusion protein, generated by the t(8;21), is the most common fusion protein in acute myeloid leukemia (AML)...
  22. Measuring change in Alzheimer's disease dysfunction more precisely with IRT
    Steve Balsis; Fiscal Year: 2012
    ..To do this we will extend our preliminary cross-sectional findings for this measure, the MMSE, and the CDR, to examine data longitudinally in Baylor College of Medicine's Alzheimer's Disease and Memory Disorder ..
  23. Feasibility of Supercritical Carbon Dioxide Sterilization for Absorbable Suture M
    JANET L HUIE; Fiscal Year: 2013
    ..Ethylene oxide (ETO) and gamma irradiation ([unreadable] irradiation) are the only technologies commercially available for medical ..
  24. Sayyed Kaleem Zaidi; Fiscal Year: 2014
    ..disrupts the gene for a key hematopoietic Runx1/AML1 transcription factor and encodes the leukemic AML1-ETO protein...
  25. Robert G Roeder; Fiscal Year: 2015
    ..proposal, we seek to use this new strategy to target the leukemogenic fusion protein/transcription factor, AML1-ETO, that is most frequently involved in acute myeloid leukemia...
  26. The role of MTG8 in transcriptional elongation and leukemia
    Kristy Stengel; Fiscal Year: 2013
    ..translocation in acute myeloid leukemia (AML), the result of which is the expression of the AML1-ETO (RUNX1-MTG8) fusion protein...
  27. LOW-DOSE RADIATION STERILIZATION
    SHALABY SHALABY; Fiscal Year: 2000
    Ethylene oxide (ETO) and gamma-irradiation (GR) are most commonly used for device sterilization by the biomedical industry...
  28. Enhanced Management of Ethylene Oxide Sterilizers
    Sudipto Majumdar; Fiscal Year: 2005
    The effectiveness of ethylene oxide (EtO) for destroying pathogens in the case of heat and moisture sensitive materials has led to its wide spread use in sterilization processes...
  29. DEVELOPMENT OF A LOW-COST ETHYLENE OXIDE DETECTOR
    David Hyatt; Fiscal Year: 1990
    ..the feasibility and develop towards commercialization a low-cost, reliable detector to monitor ethylene oxide (EtO) down to the 0.1 ppm level...
  30. EVALUATING EXPOSURES UNDER OSHAS 1984 ETO STANDARD
    Robert Herrick; Fiscal Year: 2001
    We propose to conduct a historical evaluation of worker exposures under OSHA's 1984 ethylene oxide (EtO) standard. Most potentially-exposed workers are women employed in the hospital sector where EtO is used to sterilize medical devices...
  31. Role of Vav and Rac in KIT oncogenesis
    Reuben Kapur; Fiscal Year: 2013
    ..leukemias that bear either the t(8;21) or inv(16) cytogenetic abnormality, generating the fusion genes AML1- ETO or CBF[unreadable]-MYH11, respectively...
  32. Function of MTG16/ETO2 in acute leukemia
    SCOTT HIEBERT; Fiscal Year: 2010
    ..In addition, deletion of MTG16 is observed in up to 40% of the most common form of breast cancer. ETO/MTG8 (RUNX1T1) is a closely related protein, which is disrupted by the t(8;21), which is one of the most frequent ..
  33. The role of Immunoglobulin CDRH3 in Autoimmune Disease
    HARRY WILLIAM SCHROEDER; Fiscal Year: 2012
    ..It is our hypothesis that failure to properly regulate one specific part of the antibody, CDR-H3, in susceptible individuals facilitates production of anti-DNA antibodies and triggers disease...
  34. ERIC M VERDIN; Fiscal Year: 2014
    ..We also found that the inhibitor of DNA methylation, 5-aza-2'deoxycytidine (aza-CdR), synergizes with NF-B activators to reactivate latent HIV...
  35. Dong Er Zhang; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): AML1-ETO is a DNA binding fusion protein generated from t(8;21)(q22;q22)...
  36. David A Scheinberg; Fiscal Year: 2016
    Over the last 15 years on this grant, we have established that biologically active, CDR grafted humanized IgG, novel radioconjugates and toxin conjugates, many based on the anti-CD33 Ig HuM195, can be constructed, characterized, and ..
  37. Michael R Green; Fiscal Year: 2016
    ..We have recently found that BCR-ABL, as well as two other leukemogenic fusion-proteins, CBFB-MYH11 and RUNX1-ETO, can, like RAS and BRAF, induce senescence in primary human fibroblasts and hematopoietic progenitors...
  38. Anaerobic shock as a novel treatment for tuberculosis
    Xilin Zhao; Fiscal Year: 2010
    ..of multiple drug- resistant (MDR) infections and the emergence of extensively/completely drug-resistant (XDR/CDR) tubercle bacilli are making currently chemotherapies less and less effective...
  39. t(8;21) and SON in Blood Cell Proliferation and Differentiation
    Dong Er Zhang; Fiscal Year: 2013
    ..This translocation leads to the fusion of the AML1 and ETO genes and generates various forms of AML1-ETO fusion proteins...
  40. Kate Rittenhouse-Olson; Fiscal Year: 2014
    ..Humanization will precede using modified CDR grafting onto the human antibody molecule variable sequence found to be most like the JAA-F11 mouse sequence in ..
  41. Christopher A Klug; Fiscal Year: 2014
    ..and (3), Characterize whether recurrent cytogenetic abnormalities found in AML, including the translocations AML1-ETO, inv(16), or NUP98-HOXA9, can preserve HSC self-renewal in the presence of activated Akt or NF-?B...
  42. Histone Deacetylase Inhibitor Based Therapy of AML
    Kapil Bhalla; Fiscal Year: 2011
    ..g., AML1/ETO and TEL/AML1) that act as the dominant inhibitors of transcription through the recruitment of nuclear corepressors/..
  43. MECHANISMS OF DE NOVO METHYLATION IN CANCER
    Peter A Jones; Fiscal Year: 2013
    ..This research has led to the recent approval by the FDA of two DNA demethylating agents (5-aza-CR and 5-aza-CdR) for the treatment of myeloid dysplastic syndrome...
  44. MOLECULAR ANALYSIS OF CD8, MHC CLASS I INTERACTION
    Paula B Kavathas; Fiscal Year: 2012
    ..We identified critical residues on the CDR-like loops of the immunoglobulin-like domain CD8b protein required for binding to pMHC1 as well as mutants that led ..
  45. Epigenetic alterations underlying tumorigenic potential of Glioblastoma Cells
    Theresa K Kelly; Fiscal Year: 2012
    ..with this information, in the independent phase, I will treat GBM cells with the DNA demethylating agent 5-Aza-CdR and measure the ability of demethylation to restore normal gene expression patterns and resolve aberrant chromatin ..
  46. Analysis of a murine model of the AML1-ETO translocation
    CHRISTOPHER KLUG; Fiscal Year: 2009
    The t(8;21)(q22;q22) translocation, which fuses the ETO gene on human chromosome 8 with the AML1 gene on chromosome 21, is one of the most frequent cytogenetic abnormalities associated with acute myeloid leukemia (AML)...
  47. Irving L Weissman; Fiscal Year: 2015
    ..In 2000 we found that only multipotent progenitor (MPP) stage cells in human AML with AML1-ETO translocations are leukemia cells;more importantly, in the same patients, the translocation is present in normal ..
  48. Scott W Hiebert; Fiscal Year: 2016
    ..known as AML1), including the DNA binding domain, to nearly all of Myeloid Translocation Gene on chromosome 8 (MTG8, also known as ETO)...
  49. Jeffrey J Gray; Fiscal Year: 2015
    ..work has isolated the most critical challenges: most of the antibodies in the human repertoire have hypervariable CDR H3 loops longer than that which is predictable using current loop methods;backbone conformational uncertainty and ..
  50. Rachel P Berger; Fiscal Year: 2014
    ..We have also derived a sensitive and specific clinical decision rule (CDR) for predicting ICN using easily measured clinical and laboratory variables...
  51. Molecular studies of lipid presentation and T cell recognition of CD1c
    ERIN JUNE ADAMS; Fiscal Year: 2013
    ..and/or cytotoxicity) and the sequence of their TCRs, specifically to determine whether there are motifs in the CDR loops that are used in this recognition process...
  52. Allison Ross Eckard; Fiscal Year: 2016
    ..25(OH)D concentrations to >30 ng/mL improves CVD risk and inflammation to a greater degree than increasing eto 20 ng/mL (the concentration some experts consider optimal for cardiovascular health), and (3) a "high dose" of oral ..
  53. Characterization of Pathogenic T cells in Alopecia Areata
    EMANUAL M MAVERAKIS; Fiscal Year: 2012
    ..T cells can be identified, characterized and followed longitudinally in patients with alopecia areata by combining CDR-3 length repertoire analysis with magnetic sorting and flow cytometry...
  54. The role of MTG8 in genomic stability and colorectal cancer development
    Laura DeBusk; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): MTG8 is a member of the MTG family of transcriptional co-repressors, first identified due to their frequent translocations in leukemia...
  55. Daniel Starczynowski; Fiscal Year: 2016
    ..We recently identified miR-146a, which is near the distal CDR, to be significantly reduced in del(5q) MDS patients...
  56. BEHZAD MOSLEHI; Fiscal Year: 2015
    ..at the Stanford Medical School, Professor Mark Cutkosky's group at the Stanford Center for Design Research (CDR) and HeartVista, for clinical imaging platform software integration...
  57. Mary Clyde Pierce; Fiscal Year: 2015
    ..b>CDR modeling will be performed using a binary recursive partitioning algorithm...
  58. Janey L Wiggs; Fiscal Year: 2016
    ..primary focus of identifying genes contributing to the POAG-related quantitative endophenotype, cup-to-disc ratio (CDR)...
  59. Lei Liu; Fiscal Year: 2015
    ..methods will be applied to empirical case studies using three real-world databases: Clinical Data Repository (CDR) at the University of Virginia (UVA) Health System, Medical Expenditure Panel Survey (MEPS), and the SEER- Medicare ..
  60. MULTIPLE CHIMERIC TRANSCRIPTS IN THE T(3--21)
    Giuseppina Nucifora; Fiscal Year: 1999
    ..In the 8;21 translocation in acute myeloid leukemia, AML1 fuses to ETO at 8q22. ETO also is a transcription factor based on proline-rich regions and two zinc finger motifs...
  61. HIV-1 Neutralizing Antibody Binding to Viral Membrane Mimics
    Stefan Zauscher; Fiscal Year: 2013
    ..2) CDR H3 loops on 2F5 and 4E10 embed selectively into mobile domains on HIV-1 Env mimetic membranes...
  62. TARGETING THE B-CELL RECPTOR COMPLEX AND DOWNSTREATM KINASES
    Sydney Welt; Fiscal Year: 2010
    ..Previous strategies to target the BCRC molecules in B-cell malignancies have focused on the unique CDR sequences specific for each monoclonal tumor...
  63. JOHN HACKETT BUSHWELLER; Fiscal Year: 2014
    ..of a fusion protein containing the N-terminus of Runx1, including the Runt domain, fused to almost all of ETO. The AML1-ETO fusion protein acts as a dominant repressor of core binding factor function, dysregulating the ..
  64. PATHOGENESIS AND PREVENTION OF IDDM
    Hugh McDevitt; Fiscal Year: 2002
    ..These T cell receptor V beta and V alpha sequences have detectable shared CDR 3 sequence motifs, suggesting an antigen specific T cell response...
  65. HANDHELD MONITOR FOR ETHYLENE OXIDE IN HOSPITALS
    WILLIAM PENROSE; Fiscal Year: 1990
    Ethylene oxide (EtO) is a useful agent for sterilizing medical equipment because it involves no heat and is not corrosive to most materials...
  66. MOLECULAR PATHOGENESIS OF MYELOID LEUKEMIA
    Stephen Nimer; Fiscal Year: 1999
    ..revised proposal is to understand the molecular pathogenesis of human acute myeloid leukemia (AML), using the AML-1/ETO chimeric transcription factor as a model system...
  67. ROLE OF THE GALLBLADDER IN PATHOGENESIS OF GALLSTONES
    LESTER WILLIAMS; Fiscal Year: 1991
    ..Since (1) GB stasis with increased cystic duct resistance (CDR) occurs early after initiating a lithogenic diet before crystals occur; (2) since increased GB prostaglandin (PG) ..
  68. Molecular Analysis of Del(9q) Acute Myeloid Leukemia
    David A Sweetser; Fiscal Year: 2010
    ..Our hypothesis is that a gene or genes on chromosome 9q cooperates with AML1-ETO in eukemogenesis...
  69. The Role of CBFb-MYH11 in Acute Myeloid Leukemia
    James C Mulloy; Fiscal Year: 2010
    ..We have successfully used this system to model the related leukemia fusion protein AML1-ETO. The specific aims of this proposal are as follows: Aim 1: Define the signaling pathways downstream of CBF(3-MYH11...
  70. Mechanisms of Cutaneous Drug Reactions
    CRAIG SVENSSON; Fiscal Year: 2004
    Cutaneous drug reactions (CDR) are among the most frequent adverse medical events. Recent studies suggest that between 30 and 45 percent of all adverse drug reactions involve the skin...
  71. CLONOTYPIC PCR FOR MINIMAL RESIDUAL DISEASE IN LYMPHOMA
    Ariela Noy; Fiscal Year: 2002
    ..The sequences of greatest diversity comprising complementarity region-III (CDR-III) or the V-beta counterpart provide excellent targets for clone specific MRD probes...
  72. Radioimmunotherapy: An Anti-Neoplastic Strategy
    Andres Forero; Fiscal Year: 2006
    ..3. The immunogenicity of mCC49, the long half-life (50h) and the projected even longer half-life of a chimeric or CDR-grafted version led to studies directed at humanization with deletion of various parts in search of a construct ..
  73. CHARACTERIZATION OF COREPRESSOR N-COR COMPLEXES
    Jiemin Wong; Fiscal Year: 2005
    ..repression by unliganded TR and RAR and by many other transcription factors including Mad/Max, BCL6/LAZ3 and ETO. Thus, N-CoR and SMRT are likely to play fundamental roles in development, differentiation and tumorigenesis ..